IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES

IntroductionThe discovery and development of novel treatments is a lengthy and costly endeavor: for drug candidates entering clinical trials between 1989 and 2002, the estimated cost per new drug varied from approximately 500 million to more than 2 billion U.S. dollars. Biomarkers – objective and me...

Full description

Saved in:
Bibliographic Details
Published inTranslational Medicine and Drug Discovery pp. 222 - 264
Main Authors T. Tauscher, Johannes, Schwarz, Adam J.
Format Book Chapter
LanguageEnglish
Published Cambridge University Press 31.01.2011
Subjects
Pharmaceuticals
Pharmaceuticals, Cosmetics & Toiletries
Online AccessGet full text

Cover

Table of Contents:
  • 9.1 Introduction 9.2 Molecular Imaging: PET "Receptor Occupancy" as a Marker for Target Engagement 9.3 Functional Imaging: fMRI as a Probe of Drug Effects in the CNS 9.4 Imaging as a Biomarker to Enrich Study Populations 9.5 Oncology 9.6 Imaging Cardiovascular Disease 9.7 Conclusions 9.8 Conflict of Interest Statement 9.9 References